SCHEMBL3748877

SCHEMBL3748877

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=NO)CC[C@@]43C)[C@@H]1[C@@H]1C[C@@H]1[C@@H]2C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 4/20 0.42
CYP17A1 P05093 4/20 0.41
LMNA P02545 6/20 0.40
CYP3A4 P08684 6/20 0.40
AR P10275 4/20 0.40
HSD17B10 Q99714 4/20 0.40
TSHR P16473 4/20 0.40
MAPT P10636 4/20 0.40
NR3C1 P04150 3/20 0.40
PGR P06401 3/20 0.40
SERPINA6 P08185 3/20 0.40
GPBAR1 Q8TDU6 3/20 0.40
SIGMAR1 Q99720 3/20 0.40
CYP19A1 P11511 3/20 0.40
MAPK1 P28482 3/20 0.40
SNCA P37840 2/20 0.40
CACNA1C Q13936 2/20 0.40
CYP51A1 Q16850 2/20 0.40
OR51E2 Q9H255 1/20 0.40
ESR1 P03372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748874 1.00 SHBG (0.42) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL3744150 0.84 SHBG (0.57) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL13335955 0.84 SHBG (0.57) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL3752458 0.84 SHBG (0.57) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL3749413 0.84 SHBG (0.57) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL3748880 0.76 AR (0.44) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL3747283 0.76 CYP17A1 (0.58) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL3748817 0.74 CYP17A1 (0.56) SHBGCYP17A1LMNACYP3A4AR
SCHEMBL26333875 0.74 CYP19A1 (0.70) SHBGLMNACYP3A4ARHSD17B10
SCHEMBL3363558 0.74 CYP19A1 (0.70) SHBGLMNACYP3A4ARHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE BAYER SCHERING PHARMA AG (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE HSD17B11, HSD17B7, NR5A1 SHBG 24/4885CYP17A1 4/4885LMNA 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.